GM1 ganglioside restores dopaminergic neurochemical and morphological markers in aged rats

Neuroscience

Volumn 92, Issue 3, 1999, Pages 991-1000

  Goettl, V M ^a   Wemlinger, T A ^a   Duchemin, A M ^a   Neff, N H ^a   Hadjiconstantinou, M ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Ageing; Dopamine; GM1 ganglioside; Striatum; Substantia nigra; Tyrosine hydroxylase

Indexed keywords

DOPAMINE; GANGLIOSIDE GM1; TYROSINE 3 MONOOXYGENASE;

AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CHOLINERGIC NERVE CELL; COGNITIVE DEFECT; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; INTRAPERITONEAL DRUG ADMINISTRATION; LEARNING; MALE; NERVE CELL LESION; NEUROTROPISM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA;

3,4-DIHYDROXYPHENYLACETIC ACID; AGING; ANIMALS; CORPUS STRIATUM; DOPAMINE; G(M1) GANGLIOSIDE; MALE; MESENCEPHALON; NEURONS; RATS; RATS, SPRAGUE-DAWLEY; SUBSTANTIA NIGRA; TISSUE DISTRIBUTION; TYROSINE 3-MONOOXYGENASE;

EID: 0033062035     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(98)00756-8     Document Type: Article

References (60)

1. Algeri S., Bonati M., Brunello N., Ponzio F. Dihydropteridine reductase and tyrosine hydroxylase activities in rat brain during development and senescence: a comparative study. Brain Res. 132:1977;569-574.
2. Baker H., Franzen L., Stone D., Cho J.Y., Margolis F.L. Expression of tyrosine hydroxylase in the aging, rodent olfactory system. Neurobiol. Aging. 16:1995;119-128.
3. Bennett D.A., Beckett L.A., Murray A.M., Shannon K.M., Goetz C.G., Pilgrim D.M., Evans D.E. Prevalence of parkinsonian signs and associated mortality in a community population of older people. New Engl. J. Med. 334:1996;71-76.
4. Burwell R.D., Lawler C.P., Gallagher M. Mesostriatal dopamine markers in aged Long-Evans rats with sensorimotor impairment. Neurobiol. Aging. 16:1995;175-186.
5. Carfagna N., Trunzo F., Moretti A. Brain catecholamine content and turnover in aging rats. Expl Geront. 20:1985;265-269.
6. Cho S., Duchemin A.-M., Neff N.H., Hadjiconstantinou M. Modulation of tyrosine hydroxylase and aromatic L-amino acid decarboxylase after inhibiting monoamine oxidase-A. Eur. J. Pharmac. 314:1996;51-59.
7. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Analyt. Biochem. 162:1987;156-159.
8. Dahlstrom A., Fuxe K. Evidence for the existence of monoamine-containing neurons in the central nervous system. Acta physiol. scand. 62(Suppl. 232):1964;1-55.
9. +: the consequences of treatment with GM1 ganglioside. Brain Res. 742:1996;260-264.
10. De La Cruz C., Revilla E., Venero J.L., Ayala A., Cano J., Machado A. Oxidative inactivation of tyrosine hydroxylase in substantia nigra of aged rats. Free Rad. Biol. Med. 20:1996;53-61.
11. Duchemin A.-M., Neff N.H., Hadjiconstantinou M. Induction of Trk phosphorylation by GM1 ganglioside in rat brain. J. Neurochem., Suppl. 69:1997;S33.
12. Eaton M.J., Gudehithlu K.P., Quach T., Silvia C.P., Hadjiconstantinou M., Neff N.H. Distribution of aromatic L-amino acid decarboxylase mRNA in mouse brain by in situ hybridization histology. J. comp. Neurol. 337:1993;640-654.
13. 18F-DOPA uptake: absence of aging effect. J. cerebr. Blood Flow Metab. 13:1994;881-888.
14. Emerich D.F., McDemott P., Krueger P., Banks M., Zhao J., Marszalkowski J., Frydel B., Winn S.R., Sanberg P.R. Locomotion of aged rats: relationship to neurochemical but not morphological changes in nigrostriatal dopaminergic neurons. Brain Res. Bull. 32:1993;477-486.
15. Emerich D.F., Plone M., Francis J., Frydel B.R., Winn S.R., Lindner M.D. Allevation of behavioral deficits in aged rodents following implantation of encapsulated GDNF-producing fibroblasts. Brain Res. 736:1996;99-110.
16. Farooqui T., Franklin T., Pearl D.K., Yates A.L. Ganglioside GM1 enhances induction by nerve growth factor of a putative dimer of Trk A. J. Neurochem. 68:1997;2348-2355.
17. Felten D.L., Felten S.Y., Fuller R.W., Romano T.D., Smalstig E.B., Wong D.T., Clemens J.A. Chronic dietary pergolide preserves nigrostriatal neuronal integrity in aged Fischer-344 rats. Neurobiol. Aging. 13:1992;339-351.
18. Fernandez-Ruiz J., De Miguel R., Harnandez M.L., Cebeira M., Ramos J.A. Comparisons between brain dopaminergic neurons of juvenile and aged rats: sex-related differences. Mech. Agng Devl. 63:1992;45-55.
19. Ferrari G., Anderson B.L., Stephens R.M., Kaplan D.R., Greene L.A. Prevention of apoptotic neuronal death by GM1 ganglioside. Involvement of Trk neurotrophin receptors. J. biol. Chem. 270:1995;3074-3080.
20. Finch C.E. Neuron atrophy during aging: programmed or sporadic? Trends Neurosci. 16:1993;104-110.
21. Fong T.G., Neff N.H., Hadjiconstantinou M. Systemic administration of GM1 ganglioside increases choline acetyltransferase activity in the brain of aged rats. Expl Neurol. 132:1995;157-161.
22. Fong T.G., Neff N.H., Hadjiconstantinou M. GM1 and NGF synergism on choline acetyltransferase and choline uptake in aged brain. Neurobiol. Aging. 16:1995;917-923.
23. Fong T.G., Neff N.H., Hadjiconstantinou M. GM1 ganglioside improves spatial learning and memory of aged rats. Behav. Brain Res. 85:1997;203-211.
24. Fong T.G., Neff N.H., Hadjiconstantinou M. Morphological changes of ChAT- or p75-immunopositive neurons in the aged rat following treatment with GM1 ganglioside. Soc. Neurosci. Abstr. 22:1996;742.
25. Ghidoni R., Fiorilli A., Trinchera M., Venerando B., Chigorno V., Tettamanti G. Uptake, cell penetration and metabolic processing of exogenous administered GM1 ganglioside in rat brain. Neurochem. Int. 4:1989;455-465.
26. Hadjiconstantinou M., Karadsheh N.S., Rattan A.K., Tejwani G.A., Fitkin J.G., Neff N.H. GM1 ganglioside enhances cholinergic parameters in the brain of senescent rats. Neuroscience. 46:1992;681-686.
27. Hadjiconstantinou M., Neff N.H. Differential recovery of dopamine synthetic enzymes following MPTP and the consequences of GM1 ganglioside treatment. Eur. J. Pharmac. 181:1990;137.
28. Hadjiconstantinou M., Neff N.H. GM1 ganglioside: in vivo and in vitro trophic actions on central neurotransmitter systems. J. Neurochem. 70:1998;1335-1345.
29. Hadjiconstantinou M. and Neff N. H. (1998) GM1 and the aged brain. In Sphingolipids as Signaling Modulators in the Nervous System (eds Ledeen R. W., Hakomori S., Schneider J. S., Yates A. J. and Yu R. K.), Vol. 845, pp. 225-231. New York Academy of Science.
30. Hakomori S.-I., Igarashi Y. Gangliosides and glycosphingolipids as modulators of cell growth, adhesion and transmembrane signaling. Adv. Lipid Res. 25:1993;147-162.
31. Herbert A.M., Gerhard G.A. Behavioral and neurochemical effects of intranigral administration of glial cell line-derived neurotrophic factor on aged Fischer 344 rats. J. Pharmac. exp. Ther. 282:1997;760-768.
32. Himi T., Cao M., Mori N. Reduced expression of the molecular markers of dopaminergic neuronal atrophy in the aging rat brain. J. Geront. 50A:1995;B193-B200.
33. Juorio A.V., Walz W., Sloley B.D. Absence of decarboxylation of some aromatic L-amino acids by cultured astrocytes. Brain Res. 426:1987;183-186.
34. Kish S.J., Zhong X.H., Hornykiewicz O., Haycock J.W. Striatal 3,4-dihydroxyphenylalanine decarboxylase in aging: disparity between postmortem and positron emission tomography studies? Ann. Neurol. 38:1995;260-264.
35. Lapchak P.A., Miller P.J., Jiao S. Glial cell line-derived neurotrophic factor induces the dopaminergic and cholinergic phenotype and increases locomotor activity in aged Fischer 344 rats. Neuroscience. 77:1997;745-752.
36. Lapchak P.A., Gash D.M., Collins F., Hilt D., Miller P.J., Araujo D.M. Pharmacological activities of glial cell line-derived neurotrophic factor (GDNF): preclinical development and application to the treatment of Parkinson's disease. Expl Neurol. 145:1997;309-321.
37. Li X.-M., Juorio A.V., Paterson I.A., Walz W., Zhu M.-Y., Boulton A. Gene expression of aromatic L-amino acid decarboxylase in cultured rat glial cells. J. Neurochem. 59:1992;1172-1175.
38. Lindsay R.M., Altar C.A., Cedarbaum J.M., Hyman C., Wiegand S.J. The therapeutic potential of neurotrophic factors in the treatment of Parkinson's disease. Expl Neurol. 124:1993;103-118.
39. Mason I. The GDNF receptor: recent progress and unanswered questions. Molec. cell. Neurosci. 8:1996;112-119.
40. McGeer P.L., McGeer E. Enzymes associated with the metabolism of catecholamines, acetylcholine, and GABA in human controls and patients with Parkinson's disease and Huntington's chorea. J. Neurochem. 27:1976;65-76.
41. McGeer E.G., Fibiger H.C., McGeer P.L., Wickson V. Aging and brain enzymes. Expl Geront. 6:1971;391-396.
42. Moretti A., Carfagna N., Trunzo F. Effect of aging on monoamines and their metabolites in rat brain. Neurochem. Res. 22:1987;1035-1039.
43. Morgan D. G. and May P. C. (1990) Age-related changes in synaptic neurochemistry. In Handbook of the Biology of Aging, 3rd edn (eds Schneider E. L. and Rowe J. W.), pp. 219-254. Academic, New York.
44. Mortimer J.A. Human motor behavior and aging. Ann. N. Y. Acad. Sci. 515:1988;54-66.
45. Mutoh T., Tokuda A., Miyadai T., Hamaguchi M., Fujiki N. Ganglioside GM1 binds to the Trk protein and regulates receptor function. Proc. natn. Acad. Sci. U.S.A. 92:1995;5087-5091.
46. Palmer A.M., DeKosky S.T. Monoamine neurons in aging and Alzheimer's disease. J. neural Transm. (Gen. Sect.). 91:1993;135-159.
47. Paxinos G. and Watson C. (1982) The Rat Brain in Stereotaxic Coordinates. Academic, New York.
48. Rabin S.J., Mocchetti I. GM1 ganglioside activates the high-affinity nerve growth factor receptor trkA. J. Neurochem. 65:1995;347-354.
49. Reinhard J.F., Miller D.B., O'Callaghan J.P. The neurotoxin MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) increases glial fibrillary acidic protein and decreases dopamine levels of the mouse striatum: evidence for glial response to injury. Neurosci. Lett. 95:1988;246-251.
50. Ren Q., Duchemin A.-M., Neff N.H., Hadjiconstantinou M. GM1 increases the activity of MAP kinase in brain slices. J. Neurochem., Suppl. 70:1998;S14B.
51. Roth G.S., Joseph J.A. Age-related changes in transcriptional and posttranscriptional regulation of dopaminergic system. Life Sci. 55:1994;2031-2035.
52. Sawle G.V., Colebatch J.G., Shah A., Brooks D.J., Marsden C.D., Frackowiak R.S.T. Striatal function in normal aging: implications for Parkinson's disease. Ann. Neurol. 28:1990;799-804.
53. Schneider J.S. The therapeutic role of gangliosides in neurological disorders. Drug Therapy. 1:1994;213-222.
54. Schuligoi R., Fernandez J., Heavens R.P., Sirinathsinghji D.J.S. Decreased tyrosine hydroxylase mRNA but not cholecystokinin mRNA in the pars compacta of the substantia nigra and ventral tegmental area of aged rats. Molec. Brain Res. 19:1993;333-338.
55. Strong R., Samorajski T., Gottesfeld Z. Regional mapping of neostriatal neurotransmitter systems as a function of aging. J. Neurochem. 39:1982;831-836.
56. Sudarsky L., Ronthal M. Gait disorders among elderly patients. A survey study of 50 patients. Archs Neurol. 40:1983;740-743.
57. Svennerholm L., Gottfries C.G., Blennow K., Fredman P., Karlsson I., Mansson J.E., Toffano G., Wallin A. Parenteral administration of GM1 ganglioside to presenile Alzheimer patients. Acta neurol. scand. 81:1990;48-53.
58. Venero J.L., Machado A., Cano J. Changes in monoamines and their metabolite levels in substantia nigra of aged rats. Mech. Agng Devl. 49:1989;227-233.
59. Venero J.L., Machado A., Cano J. Turnover of dopamine and serotonin and their metabolites in the striatum of aged rats. J. Neurochem. 56:1991;1940-1948.
60. Weihmuller F.B., Hadjiconstantinou M., Bruno J.P., Neff N.H. Continued administration of GM1 ganglioside is required to maintain recovery from neuroleptic-induced sensorimotor deficits in MPTP-treated mice. Life Sci. 45:1989;2495-2502.